Related Experiment Videos
Metastatic dedifferentiated chordoma with elevated beta-hCG: a case report
Hidayatullah G Munshi1, Sofia D Merajver, Riccardo Valdez
1Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor 48109-0948, USA.
American Journal of Clinical Oncology
|June 1, 2002
Summary
Dedifferentiated chordoma is an aggressive bone tumor with a high risk of metastasis. This case highlights a rare presentation with elevated beta-human chorionic gonadotropin, suggesting chemotherapy may benefit systemic disease management.
Area of Science:
- Oncology
- Pathology
Background:
- Chordomas are rare bone tumors, with dedifferentiated chordomas representing less than 10% of cases.
- Dedifferentiated chordomas exhibit increased clinical aggressiveness and a propensity for early distant metastases compared to typical chordomas.
Observation:
- A case report details a 24-year-old male diagnosed with dedifferentiated chordoma.
- The patient presented with multiple pulmonary metastases and an elevated serum beta-human chorionic gonadotropin level.
Findings:
- The patient's condition rapidly declined, leading to death before treatment initiation.
- The elevated beta-human chorionic gonadotropin level in this context is a notable laboratory finding.
Implications:
- This case underscores the aggressive nature of dedifferentiated chordoma.
- Chemotherapy may be a potential therapeutic strategy for managing systemic disease in dedifferentiated chordoma patients.